DAIICHI SANKYO, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Study to Assess the Effect of a CYP3A Weak Inducer Rufinamide on Quizartinib Pharmacokinetics in Healthy Subjects
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 32
- Registration Number
- NCT06740825
- Locations
- 🇺🇸
WCT, San Antonio, Texas, United States
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 12
- Registration Number
- NCT06740799
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Advanced Pharma, Miami, Florida, United States
🇺🇸GCP Research, Saint Petersburg, Florida, United States
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 726
- Registration Number
- NCT06731478
A Study Assessing Risk Factors for Oral Mucositis/Stomatitis and Ocular Surface Events in NSCLC and Breast Cancer
- Conditions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 13759
- Registration Number
- NCT06686602
- Locations
- 🇺🇸
ConcertAI Database, Cambridge, Massachusetts, United States
A Study of Raludotatug Deruxtecan in Participants With Advanced/Metastatic Solid Tumors (REJOICE-PanTumor01)
- Conditions
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 200
- Registration Number
- NCT06660654
- Locations
- 🇺🇸
Clinical Research Alliance, Westbury, New York, United States
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
- Conditions
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 137
- Registration Number
- NCT06644768
- Locations
- 🇺🇸
University of California San Diego (Ucsd)-Moores Cancer Center, La Jolla, California, United States
🇺🇸California Research Institute, Los Angeles, California, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 150
- Registration Number
- NCT06644755
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
A Study of Ifinatamab Deruxtecan in Subjects With Advanced or Metastatic ESCC (IDeate-Esophageal01)
- Conditions
- Interventions
- First Posted Date
- 2024-10-16
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 510
- Registration Number
- NCT06644781
A Study of Real-world Treatment Patterns and Outcomes in Chinese Advanced NSCLC Patients Who Previously Received at Least 2 Line Treatments
- Conditions
- Interventions
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 1200
- Registration Number
- NCT06617390
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
🇨🇳The First Affiliated Hospital of Fujian Medical University, Fuzhou, China
🇨🇳Beijing Cancer Hospital, Beijing, China
A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
- Conditions
- Interventions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 800
- Registration Number
- NCT06585501
- Locations
- 🇨🇳
Liaoning Cancer Hospital & Institute, Shenyang, China
🇨🇳Harbin Medical University Cancer Hospital, Harbin, China
🇨🇳Affiliated Cancer Hospital of Shandong First Medical University, Jinan, China